东吴证券指出，从经济基本面看，今年留给美联储降息的窗口不多，宽财政对经济的脉冲效应还在路 上。一季度美联储不降息的话，港股反弹节奏就更要看分子端情况。港股整体配置维持哑铃策略，建议 控制配置仓位，等待更多消息释放。价值红利为底仓，进攻方向继续关注市场共识，AI科技、有色、 创新药。 港股今日冲高回落，恒指早盘一度冲破两万七，恒科指数午后则一度转跌。截止收盘，恒生指数涨 0.9%或239.99点，报26848.47点，全日成交额为3151.92亿港元；恒生国企指数涨0.71%，报9285.41点； 恒生科技指数涨0.11%，报5869.79点。 蓝筹股表现 药明康德（603259）(02359)领涨蓝筹。截至收盘，涨8.3%，报120港元，成交额14.22亿港元，贡献恒指 6.85点。1月12日晚，药明康德公布，公司全年预计实现营业收入454.56亿元，同比增长15.84%；其 中，持续经营业务收入同比增长约21.40%。预计经调整归母净利润149.57亿元，同比增长约41.33%；归 属于公司股东的净利润191.51亿元，同比增长约 102.65%。 其他蓝筹股方面，药明生物(02269)涨5.85%，报39 ...

Market Performance - The Hong Kong stock market saw a significant early rise but narrowed gains in the afternoon, with the Hang Seng Index closing at 26,848.47 points, up 239.99 points, or 0.90% [1] - The total trading volume for the day was 315.2 billion HKD, showing a slight increase compared to the previous day [1] Sector Highlights - Gold stocks continued their upward trend, with China Gold International (HK02099) rising over 7%, Lingbao Gold (HK03330) up nearly 3%, and Zijin Mining (HK01818) and Shandong Gold (HK01787) both increasing over 2% [3] - The Hang Seng Tech Index closed at 5,869.79 points, up 6.59 points, or 0.11% [4] Company News - Citigroup has aggressively raised its short-term outlook for precious metals, predicting gold prices could reach 5,000 USD/oz and silver 100 USD/oz within three months due to escalating geopolitical risks, physical shortages, and uncertainties in Federal Reserve policies [6] - Innovative drug concept stocks performed well, with WuXi AppTec (HK02359) rising over 8% [7] - WuXi AppTec announced an expected annual revenue of 45.456 billion CNY, a year-on-year increase of 15.84%, with adjusted net profit expected to rise by approximately 41.33% to 14.957 billion CNY [9] - Rongchang Biopharmaceutical (HK09995) signed an exclusive licensing agreement with AbbVie for its new dual-target PD-1/VEGF antibody drug RC148, receiving an upfront payment of 650 million USD and potential total payments of up to 5.6 billion USD [11] Market Outlook - Guosen Securities noted that the Hong Kong stock market has not yet fully strengthened, with traditional industries still dominating, and concerns over intensified competition among internet companies affecting market sentiment [13] - The pricing power of Hong Kong stocks is influenced by overseas risk appetite, and the appreciation of the RMB is being offset by profit-taking sentiment [13] - The AH premium index indicates that quality H-shares are preferred over A-shares, with domestic investors favoring leading companies through southbound channels [13]

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index rising by 0.9% to close at 26,848.47 points, and a total trading volume of HKD 315.19 billion [1] - The Hang Seng Tech Index saw a slight increase of 0.11%, closing at 5,869.79 points [1] Blue Chip Performance - WuXi AppTec (02359) led the blue-chip stocks, rising 8.3% to HKD 120, contributing 6.85 points to the Hang Seng Index. The company expects a revenue of RMB 45.456 billion for the year, a year-on-year increase of 15.84% [2] - Other notable blue-chip performances include WuXi Biologics (02269) up 5.85%, Alibaba (09988) up 3.63%, while Tingyi (00322) and China Resources Mixc Lifestyle (01209) saw declines of 4.34% and 3.32% respectively [2] Sector Highlights - The innovative drug sector showed strong performance, with companies like Rongchang Biologics (09995) rising nearly 8% after announcing a collaboration with AbbVie, which includes an upfront payment of USD 650 million [3][4] - AI healthcare stocks also gained traction, with Ark Health (06086) surging 65.82% and other related stocks like Jingtai Holdings (02228) and Alibaba Health (00241) also seeing increases [4] Geopolitical Impact - The escalation of tensions between the U.S. and Iran led to a rise in gold and oil stocks, with China Gold International (02099) increasing by 7.36% and Shandong Molong (00568) rising by 14.56% [5][6] - The geopolitical situation is expected to cause volatility in oil prices, with Citigroup predicting gold prices could reach USD 5,000 per ounce in a bullish scenario [6] New Listings and Company Developments - Three new stocks, including Zhaoyi Innovation (03986), debuted on the Hong Kong Stock Exchange, with Zhaoyi Innovation rising 37.53% [7] - Dongfeng Motor Group (00489) saw a rise of 6.79% following news of a proposed privatization plan [9] - However, Hillstone Technology (01478) faced a decline of 6.18% after a report indicated lower-than-expected camera module shipments [10]

Market Overview - The Hong Kong stock market showed a high open but low close, with cautious market sentiment. The Hang Seng Index rose by 0.9% to 26,848.47, while the Hang Seng Tech Index increased by 0.11% to 5,869.79, and the China Enterprises Index gained 0.71% to 9,285.41 [1][2]. Sector Performance - Technology stocks had mixed results, with Alibaba rising by 3.6% after previously increasing by 6.3%, while Kuaishou fell by 2.2%, and Xiaomi and Baidu dropped nearly 2% [2][4]. - Gold and precious metals surged, with spot gold reaching a new high of $4,630 per ounce and silver surpassing $86 per ounce, driven by geopolitical risks and concerns over the Federal Reserve's independence [6][7]. - Biopharmaceutical stocks were active, with WuXi AppTec rising over 8% following a positive earnings forecast, while other leading biopharma stocks also saw gains [7][8]. - Insurance stocks performed well, with China Pacific Insurance rising over 4% and China Life increasing by over 3% [11]. - Oil stocks generally rose, with CNOOC gaining over 2% and China Petroleum increasing by 1% [12]. - Automotive stocks saw broad increases, with Li Auto, Great Wall Motors, and Xpeng all rising over 2% [13]. Notable Stock Movements - WuXi AppTec projected a revenue of 45.456 billion yuan for 2025, a 15.84% increase year-on-year, with a net profit forecast of 19.151 billion yuan, reflecting a 102.65% increase [8]. - The AI healthcare sector saw significant gains, with Ark Health rising over 65% [9][10]. - Lithium battery stocks surged, with Zhongxin Innovation rising by 6.4% and Ganfeng Lithium increasing by nearly 4% [14][15]. - The commercial aerospace sector experienced a collective pullback, with Asia Pacific Satellite dropping over 9% [16]. - The brain-computer interface sector saw notable declines, with Nanjing Panda Electronics falling by 7.79% [18]. - The education sector faced widespread declines, with Minsheng Education dropping over 4% [22]. Capital Flows - Southbound funds recorded a net inflow of 1.296 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 149 million HKD and the Shenzhen-Hong Kong Stock Connect contributing 1.147 billion HKD [25]. Market Outlook - Analysts suggest that the Hong Kong stock market may continue to lag behind A-shares, with a need for time to restore investor sentiment. The market's future performance will likely be influenced by large financials, commodities, and internet sectors, with potential structural opportunities in undervalued stocks with resilient fundamentals [25].

1月13日，港股股指高开后震荡下行，截止收盘，恒生指数涨0.9%报26848.47点，恒生科技指数涨0.11% 报5869.79点，国企指数涨0.71%报9285.41点，红筹指数涨0.78%报4146.17点。 盘面上，大型科技股走势分化，阿里巴巴涨3.63%，腾讯控股涨0.72%，京东集团涨0.43%，小米集团跌 1.96%，网易跌0.18%，美团跌0.1%，快手跌2.24%，哔哩哔哩涨3.11%；创新药板块全天表现强势，药 明康德收涨8.3%；黄金股领涨，中国黄金国际涨超7%，万国黄金集团涨超5%，紫金黄金国际涨超 5%，灵宝黄金涨超3%；大模型概念股智谱跌超12%，MINIMAX跌超8%；半导体板块走弱，上海复旦 跌近5%，华虹半导体跌超2%；商业航天概念回调，金风科技跌超9%；今日三只新股上市，兆易创新涨 超37%，BBSB INTL涨超11%，红星冷链涨0.33%。 企业新闻 腾讯控股(00700.HK)：斥资约6.36亿港元回购102.4万股，回购价614-627港元。 吉利汽车(00175.HK)：斥资1.51亿港元回购900.7万股，回购价16.63-17.15港元。 钧达股份(02865. ...

Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 0.9% to close at 26,877.42 points, the Hang Seng Tech Index up by 0.11%, and the State-Owned Enterprises Index rising by 0.71% [1][7]. Sector Performance - **Technology Stocks**: Mixed performance observed, with Alibaba and Bilibili both rising over 3%, while Kuaishou fell over 2%, and Xiaomi and Baidu dropped over 1% [1][7]. - **Biopharmaceutical Sector**: Strong performance noted, particularly with WuXi AppTec rising over 8%. The upcoming JPMorgan Healthcare Conference is expected to act as a catalyst for the innovative drug market, with expectations for updates on the operational progress of Chinese innovative drug companies [3][9]. - **Gold Stocks**: Continued upward trend, with China Gold International increasing over 7%. Citigroup has aggressively raised its short-term outlook for precious metals, predicting gold prices could reach $5,000 per ounce and silver $100 per ounce within the next three months, driven by geopolitical risks, physical shortages, and uncertainties in Federal Reserve policies [3][9]. - **Commercial Aerospace Sector**: A pullback was observed, with Goldwind Technology declining over 9%. Recent shareholder sell-offs have contributed to market volatility. However, significant breakthroughs in reusable rocket technology in China are expected to reshape the cost structure of the aerospace industry, benefiting upstream companies in aerospace manufacturing, new materials, and satellite applications [3][9]. New Listings - Three new stocks were listed today, with Zhaoyi Innovation rising over 37%, BBSB International up over 11%, and Hongxing Cold Chain increasing by 0.33% [4][9].

Group 1 - The CRO and innovative drug sectors are experiencing strong gains, with stocks like Rongchang Biopharma A-shares and H-shares, WuXi AppTec, and Sanofi rising by 17%, 9%, 7.9%, and 7.2% respectively, leading to a 3.5% increase in the Tianhong Innovative Drug ETF [1] - The Tianhong Innovative Drug ETF (517380) is the only ETF tracking the Hang Seng Shanghai-Shenzhen Hong Kong Innovative Drug Selected 50 Index, focusing on 50 actively traded innovative drug and CXO companies with high R&D investment [1] - The ETF has seen a net inflow of 207 million yuan over the past five days, indicating strong investor interest [1] Group 2 - The 44th JPMorgan Global Healthcare Conference is set to take place, with over 20 domestic innovative drug companies confirmed to participate, including WuXi AppTec and several others [1] - WuXi AppTec is projected to achieve a profit of 19.151 billion yuan in 2025, representing a year-on-year increase of 103%, with Q4 net profit expected to reach 7.075 billion yuan, a quarter-on-quarter increase of 101% [1] - The sixth batch of national centralized procurement for high-value medical consumables is about to open for bidding, including 12 types of medical consumables [2] Group 3 - The medical device ETF (159873) has a significant focus on brain-machine interfaces, accounting for over 19% of its composition, indicating strong technological attributes [2] - The ETF's components include a high proportion of stocks from the Sci-Tech Innovation Board and the Growth Enterprise Market, nearly 80%, suggesting a robust growth potential [2] - The industry outlook for 2026 remains positive, with a focus on innovation, international expansion, and recovery in challenging markets, particularly in the CXO and upstream supply chain sectors [2]

Core Viewpoint - Morgan Stanley reports that WuXi AppTec has issued a positive earnings forecast, expecting a 16% year-on-year sales increase to 45.5 billion yuan in 2025, surpassing the bank's expectations by 2% [1] - Adjusted net profit is projected to rise by 41% year-on-year to 15 billion yuan, exceeding the bank's forecast by 4% [1] Group 1 - The better-than-expected performance is driven by continuous capacity and capability enhancements, production process optimization, and improved operational efficiency [1] - The market is anticipated to respond positively to the earnings forecast [1] Group 2 - Although the earnings announcement did not provide specific details on gross margin or operating expenses, the bank views the adjusted net profit margin expansion to 33% as another positive surprise [1] - The target price is set at 142 HKD with a "Buy" rating [1]

智通财经APP获悉，摩根士丹利发布研报称，仍将药明康德(02359)列为2026年首选股份，予药明康德 (603259.SH)A股目标价130元，评级"增持"；未来催化剂包括券商会议上更新的业务展望，以及地缘政 治逆风的缓和。 该行指，期内来自持续经营的收入同比升21.4%，胜管理层预期的17%至18%，主要基于化学业务的后 期研发和商业化合约，以及TIDES业务表现优异。同时，年内公司确认两项重大一次性收益，包括出售 旗下检测业务录得约14亿元收益。 药明康德2025年收入同比升15.8%至455亿元人民币(下同)，盈利升102.7%至192亿元，经调整非国际财 务报告准则盈利升41.3%至150亿元。 ...

Core Viewpoint - Morgan Stanley maintains WuXi AppTec (603259) as a top pick for 2026, setting a target price of 130 RMB for its A-shares and rating it as "Overweight" [1] Financial Performance - WuXi AppTec's revenue for 2025 is projected to increase by 15.8% to 45.5 billion RMB, while profit is expected to rise by 102.7% to 19.2 billion RMB [1] - Adjusted profit under non-IFRS standards is anticipated to grow by 41.3% to 15 billion RMB [1] Business Segments - Revenue from continuing operations is expected to grow by 21.4%, surpassing management's forecast of 17% to 18%, driven by strong performance in the chemical business and TIDES [1] - The company confirmed two significant one-time gains during the year, including approximately 1.4 billion RMB from the sale of its testing business [1]